Skip to content

Study on the innovative pathogenesis of hypertensive heart failure and its clinical management scheme - Study on the evolution of toxic evidence of hypertensive heart failure

Study on the innovative pathogenesis of hypertensive heart failure and its clinical management scheme - Study on the evolution of toxic evidence of hypertensive heart failure

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300071803
Enrollment
Unknown
Registered
2023-05-25
Start date
2023-06-01
Completion date
Unknown
Last updated
2023-06-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertensive Heart Failure

Interventions

Hypertensive Heart Failure Toxic Evidence Group:None

Sponsors

Guang'anmen Hospital, Chinese Academy of traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Meeting the diagnostic criteria for chronic heart failure: patients with stage C heart failure (clinical heart failure stage: patients with organic heart disease with previous or current signs and/or symptoms of heart failure), patients with stage D heart failure (refractory end-stage heart failure: patients with progressive organic heart disease who remain symptomatic at rest despite aggressive medical therapy and who require specific interventions); 2. Meeting the diagnostic criteria for hypertension; 3. Meeting the diagnostic criteria for toxic evidence of hypertensive heart failure; 4. NYHA class II-IV; 5. Age 18-80 years; 6. Signed informed consent form.

Exclusion criteria

Exclusion criteria: 1. Acute phase of myocardial infarction; 2. Combined severe hepatic insufficiency (ALT > 100 U/L or AST > 100 U/L), severe renal insufficiency (glomerular filtration rate 5.5 mmol/L); 3. Severe haematological disorders and malignancies; 4. Pregnancy or lactation; 5. Psychiatric patients; 6. Those with severe heart failure with a life expectancy of less than six months; 7. Difficult to control hypertension or diabetes mellitus; 8. No Chinese medicinal preparation related to this disease in the past 2 weeks.

Design outcomes

Primary

MeasureTime frame
NT-proBNP;Blood routine;hs-CRP;Blood fat;blood sugar;Ultrasonic cardiogram;Electrocardiogram;Chest radiograph;Minnesota heart failure quality of life scale ;Chinese Medicine Evidence Score;Vital signs;

Countries

China

Contacts

Public ContactJun Li

Guang'anmen Hospital, Chinese Academy of traditional Chinese Medicine

gamyylj@163.com+86 130 5145 8913

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026